Qualigen Therapeutics Future Growth
Future criteria checks 0/6
Qualigen Therapeutics is forecast to grow earnings at 4.6% per annum. EPS is expected to grow by 62.9% per annum.
Key information
4.6%
Earnings growth rate
62.9%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Nov 2023 |
Recent future growth updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?
Apr 05Qualigen nabs additional U.S. patent for ALAN anticancer platform
Dec 15Qualigen Therapeutics EPS misses by $0.61, misses on revenue
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -11 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -11 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2023 | 5 | -18 | -7 | -7 | N/A |
| 6/30/2023 | 6 | -18 | -11 | -11 | N/A |
| 3/31/2023 | 6 | -18 | -12 | -12 | N/A |
| 12/31/2022 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2022 | 1 | -15 | -14 | -14 | N/A |
| 6/30/2022 | 5 | -16 | -14 | -14 | N/A |
| 3/31/2022 | 4 | -17 | -17 | -17 | N/A |
| 12/31/2021 | 6 | -18 | -15 | -15 | N/A |
| 9/30/2021 | 5 | -7 | -15 | -15 | N/A |
| 6/30/2021 | 5 | -12 | -17 | -17 | N/A |
| 3/31/2021 | 5 | -25 | -13 | -12 | N/A |
| 12/31/2020 | 4 | -20 | -10 | -10 | N/A |
| 9/30/2020 | 5 | -28 | -8 | -7 | N/A |
| 6/30/2020 | 5 | -20 | -2 | -2 | N/A |
| 3/31/2020 | 6 | -2 | 0 | 0 | N/A |
| 12/31/2019 | 5 | -1 | -1 | -1 | N/A |
| 3/31/2019 | 6 | -1 | -1 | -1 | N/A |
| 3/31/2018 | 10 | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QLGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QLGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QLGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if QLGN's revenue is forecast to grow faster than the US market.
High Growth Revenue: QLGN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if QLGN's Return on Equity is forecast to be high in 3 years time